On August 8, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update. Arrowhead recently presented preclinical data on ARO-INHBE and introduced ARO-ALK7 at its summer seminar on obesity/metabolic disorders. We anticipate both programs entering the clinic in 2025. The company recently completed a $500 million senior secured credit facility with Sixth Street that includes $400 million funded at close and an additional $100 million available at Arrowhead's option during the seven-year agreement. Following release of topline results from the Phase 3 PALISADE study of plozasiran in FCS, the full data set will be presented at European Society of Cardiology on September 2, 2024.
